ライフサイエンスコーパス: monophosphoryl lipid A

1 co-stimulated with the TLR4-agonist adjuvant monophosphoryl lipid A.

2 OVA) 323-339 plus the inflammatory adjuvant, monophosphoryl lipid A.

3 by using the combined adjuvant of alum plus monophosphoryl lipid A.

4 AS04 comprising alum (Al) and 3-deactylated monophosphoryl lipid A (3-dMPL) afforded HSV-seronegativ

5 For example, monophosphoryl lipid A, a family of endotoxic TLR4 agoni

6 The addition of monophosphoryl lipid A, a minimally toxic derivative of

7 in approved products is AS04, which combines monophosphoryl lipid A, a TLR-4 agonist, with alum.

8 accine candidate, in conjunction with either monophosphoryl lipid A, a TLR4 agonist, or CpG, a TLR9 a

9 ificant levels of Ab reactivity in the NS1 + monophosphoryl lipid A + AddaVax group.

10 bined with aluminum and magnesium hydroxide, monophosphoryl lipid A + AddaVax, or Sigma adjuvant syst

11 ied in a dimethyldioctadecylammonium bromide-monophosphoryl lipid A adjuvant and tested for the abili

12 combinant HSV-2 glycoprotein D (gD2) in alum-monophosphoryl lipid A adjuvant only in HSV women serone

13 han the wild-type allergens and a registered monophosphoryl lipid A-adjuvanted vaccine based on natur

14 e in both flight and ground cohorts received monophosphoryl lipid A alone without additional OVA stim

15 ice with PppA protein and either a synthetic monophosphoryl lipid A analog, RC529AF, or a cholera tox

16 5/50 and 50/50 formulations) adjuvanted with monophosphoryl lipid A and Al(OH)3 We present safety and

17 led to incorporate the amphipathic adjuvants monophosphoryl lipid A and cholesterol-modified CpG olig

18 ose promoted by the well-studied TLR agonist monophosphoryl lipid A and comparable to a much larger d

19 ized with HCV-LP, HCV-LP and adjuvant AS01B (monophosphoryl lipid A and QS21), or HCV-LP and the comb

20 -in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (

21 orates two immune stimulants, 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21.

22 d vaccine adjuvant containing 3-O-desacyl-4'-monophosphoryl lipid A and the saponin QS-21.

23 nd B5R proteins in an adjuvant consisting of monophosphoryl lipid A and trehalose dicorynomycolate or

24 ke particle (VLP) vaccine (with chitosan and monophosphoryl lipid A as adjuvants) to prevent acute vi

25 model of chancroid, using either Freund's or monophosphoryl lipid A as adjuvants.

26 s toxoid and mixed with liposomes containing monophosphoryl lipid A as an adjuvant.

27 in D from HSV-2 with alum and 3-O-deacylated monophosphoryl lipid A as an adjuvant; control subjects

28 A1 was combined with commercially available monophosphoryl lipid A-based adjuvant, and after immuniz

29 In this way, the immunostimulant activity of monophosphoryl lipid A can significantly improve the imm

30 protein formulated with either Alhydrogel or monophosphoryl lipid A-containing adjuvants resulted in

31 Only mice treated with L110f plus monophosphoryl lipid A-CpG were able to induce a strong

32 A semisynthetic strategy to obtain monophosphoryl lipid A derivatives equipped with clickab

33 zation with rPhpA-79 protein adjuvanted with monophosphoryl lipid A (for subcutaneous immunization) o

34 dministration of ADX40-Id with 3-O-deacyl-4'-monophosphoryl lipid A further significantly enhanced va

35 ection induced by Leish-111f formulated with monophosphoryl lipid A in a stable emulsion (Leish-111f+

36 subunit vaccine with alum and 3-O-deacylated-monophosphoryl lipid A in subjects whose regular sexual

37 -MPL (aluminum hydroxide plus 3-O-desacyl-4'-monophosphoryl lipid A) induced robust L2 antibodies (EL

38 combination with lipopolysaccharide (LPS) or monophosphoryl lipid A led to strongly synergistic produ

39 We previously showed that monophosphoryl lipid A (MLA) activates TLR4 in dendritic

40 l fatty acid chain length in the 3-O-desacyl monophosphoryl lipid A (MLA) series is shown to be a cri

41 e used to achieve early preconditioning, and Monophosphoryl lipid A (MLA) was used to induce late pre

42 Monophosphoryl lipid A (MLA), a nontoxic analogue of end

43 s based on the structure of lipid A, such as monophosphoryl lipid A (MLA), have proven to be safe and

44 phosphoryl lipid A (dLPA) but only weakly to monophosphoryl lipid A (mLPA).

45 ss pollen allergoids containing the adjuvant monophosphoryl lipid A (MPL((R)) ); 51 control patients

46 th either a low or high dose of 3-deacylated monophosphoryl lipid A (MPL) and administered with alum

47 ps were boosted with FI-HSV2 formulated with monophosphoryl lipid A (MPL) and alum adjuvants.

48 in CHO cells and given intramuscularly with monophosphoryl lipid A (MPL) and alum, or gC2 and gD2 we

49 e particle (VLP) vaccine with 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and alum.

50 from norovirus GI.1 genotype adjuvanted with monophosphoryl lipid A (MPL) and the mucoadherent chitos

51 The effectiveness of monophosphoryl lipid A (MPL) as a mucosal adjuvant was i

52 ory molecule SA-4-1BBL with the TLR4 agonist monophosphoryl lipid A (MPL) as a novel vaccine adjuvant

53 uble truncated gD protein (gD2t) in alum and monophosphoryl lipid A (MPL) elicited high neutralizing

54 Monophosphoryl lipid A (MPL) from Salmonella typhimurium

55 Monophosphoryl lipid A (MPL) is a nontoxic derivative of

56 Monophosphoryl lipid A (MPL) is a nontoxic derivative of

57 Monophosphoryl lipid A (MPL) is an LPS-derived Toll-like

58 nsisting of glycoprotein D (gD2) in alum and monophosphoryl lipid A (MPL) reduced genital herpes dise

59 capsulation of RTS,S in liposomes containing monophosphoryl lipid A (MPL) resulted in a dose-dependen

60 essed whether prophylactic administration of monophosphoryl lipid A (MPL), a nontoxic derivative of l

61 tranasal (i.n.) immunization of rHagB and if monophosphoryl lipid A (MPL), a nontoxic derivative of t

62 e investigated whether nHgbAI dispensed with monophosphoryl lipid A (MPL), an adjuvant approved for u

63 ) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked

64 the nonspecific biological response modifier monophosphoryl lipid A (MPL), given in vivo or incubated

65 Addition of adjuvants, such as monophosphoryl lipid A (MPL), might allow for efficaciou

66 -gp160, formulated with liposomes containing monophosphoryl lipid A (MPL), MPL-AF, proteosomes, emuls

67 ng its superiority to vaccines adjuvanted by monophosphoryl lipid A (MPL)-alum.

68 y in the presence of an additional adjuvant, monophosphoryl lipid A (MPL).

69 we evaluated the effects of adjuvant AS01B (monophosphoryl lipid A [MPL] and QS21), CpG 10105, and t

70 Monophosphoryl lipid A (MPLA) is a low-toxicity derivati

71 Monophosphoryl lipid A (MPLA) is a Toll-like receptor 4

72 nal adjuvant alum or the molecular adjuvants monophosphoryl lipid A (MPLA) or alpha-galactosylceramid

73 th ovalbumin (OVA) and a molecular adjuvant, monophosphoryl lipid A (MPLA) promoted BMDC maturation a

74 inked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic

75 Monophosphoryl lipid A (MPLA), a less toxic derivative o

76 Monophosphoryl lipid A (MPLA), a low toxicity derivative

77 Monophosphoryl lipid A (MPLA), a nontoxic TLR4 ligand de

78 Immunization with these particles and monophosphoryl lipid A (MPLA), a US Food and Drug Admini

79 Surprisingly, monophosphoryl lipid A (MPLA), another TLR4 ligand, enha

80 Priming of mice with LPS, monophosphoryl lipid A (MPLA), or poly(I:C) significantl

81 cts of VTX-294 and R-848 in combination with monophosphoryl lipid A (MPLA; TLR4) were also assessed.

82 erule-derived proline-rich antigen (rPRA) in monophosphoryl lipid A-oil emulsion adjuvant or a DNA va

83 stable emulsion (SE) with the TLR4 agonists monophosphoryl lipid A or glucopyranosyl lipid A (GLA) h

84 e conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate.

85 and rabbits was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate.

86 d with alum and the detoxified LPS adjuvant, monophosphoryl lipid A, provided some protection to the

87 terol-rich liposomes containing the adjuvant monophosphoryl lipid A results in the production of anti

88 The endogenous production of calcitriol by monophosphoryl lipid A-stimulated DCs appeared to be Tol

89 reas the TLR4 ligands lipopolysaccharide and monophosphoryl lipid A substantially augmented the magni

90 A monophosphoryl lipid A-Thomson-Friedenreich (TF) antigen

91 nosinic-polycytidylic acid [poly-IC]), TLR4 (monophosphoryl lipid A), TLR7/8 (3M-012), TLR9 (CpG), or

92 is, which were eliminated by the addition of monophosphoryl lipid A to the formulation.

93 Stimulation with the TLR-4 ligand monophosphoryl lipid A together with IFN-gamma (alt-2 DC

94 adjuvant, Freund's incomplete adjuvant, and monophosphoryl-lipid A/trehalose dicorynomycolate adjuva

95 Monophosphoryl lipid A was prepared from the lipopolysac